BridgeBio Pharma
BBIO
BBIO
221 hedge funds and large institutions have $4.24B invested in BridgeBio Pharma in 2023 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 66 increasing their positions, 75 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
12% more funds holding
Funds holding: 197 → 221 (+24)
5.82% more ownership
Funds ownership: 93.34% → 99.16% (+5.8%)
12% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 75
Holders
221
Holding in Top 10
10
Calls
$91.1M
Puts
$58M
Top Buyers
| 1 | +$67.5M | |
| 2 | +$37.4M | |
| 3 | +$29M | |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$27.6M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$26.3M |
Top Sellers
| 1 | -$53.5M | |
| 2 | -$39.6M | |
| 3 | -$24.3M | |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$11.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.8M |